Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioceres Crop Solutions (BIOX) Notes Payables (2017 - 2026)

Bioceres Crop Solutions' Notes Payables history spans 10 years, with the latest figure at $66.4 million for Q1 2026.

  • On a quarterly basis, Notes Payables fell 63.34% to $66.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $66.4 million, a 63.34% decrease, with the full-year FY2025 number at $119.7 million, down 12.47% from a year prior.
  • Notes Payables hit $66.4 million in Q1 2026 for Bioceres Crop Solutions, down from $119.7 million in the prior quarter.
  • Over the last five years, Notes Payables for BIOX hit a ceiling of $181.1 million in Q1 2025 and a floor of $66.4 million in Q1 2026.
  • Historically, Notes Payables has averaged $113.8 million across 5 years, with a median of $113.7 million in 2023.
  • Biggest five-year swings in Notes Payables: skyrocketed 50.96% in 2023 and later plummeted 63.34% in 2026.
  • Tracing BIOX's Notes Payables over 5 years: stood at $71.3 million in 2022, then surged by 50.96% to $107.6 million in 2023, then rose by 27.04% to $136.7 million in 2024, then decreased by 12.47% to $119.7 million in 2025, then crashed by 44.53% to $66.4 million in 2026.
  • Business Quant data shows Notes Payables for BIOX at $66.4 million in Q1 2026, $119.7 million in Q2 2025, and $181.1 million in Q1 2025.